Life Sciences and Healthcare

Representing TESARO in its US$101m Series B financing, its IPO, and all of its follow-on equity financings and US$165m notes financing.

Advising a leading pharma company on its innovative approach regarding digital health offerings.

Global defense of TÜV Rheinland against liability claims resulting from allegedly inappropriate certification of breast implant manufacturer P.I.P.

Advising a drug company on strategies for obtaining orphan drug approval and working with scientific and regulatory groups to draft and submit designation request.

Advising a U.S. medical device company on regulatory and commercial issues regarding the market launch of a gene test in 24 European countries.

Advising MorphoSys AG in a worldwide license and collaboration agreement with Emergent Biosolutions to develop an antibody for the treatment of prostate cancer.

Handling hospital transactions for the University of Minnesota, Saint Louis University, Georgetown University, the University of Miami, the State University of New York, and more.

Instrumental in persuading FDA to change longstanding regulatory position on awarding exclusivity to fixed-dose combination products, benefitting Gilead’s products in the HIV and Hepatitis C fields.

Lead agency counsel for implementation of Affordable Care Act, including provisions governing health insurance coverage and Medicare Advantage plans.

Obtained a permanent injunction for a leading Japanese pharmaceutical firm in a bench trial on infringement and validity.

Representation of a global technology company in the creation of a joint venture to develop next-generation surgical robots.

Representing Allergan in the acquisition of rights to Ironwood Pharmaceuticals’ linaclotide product (CONSTELLA®) in more than 40 countries outside the U.S.

Representing Anthem, Inc. in more than 100 class action lawsuits that have been filed around the country related to their cyberattack. 

Representing Novartis in an exclusive global collaboration agreement with the University of Pennsylvania to develop and commercialize immunotherapies for cancer.

Representing Novartis in its landmark portfolio transformation transactions with GlaxoSmithKline and Eli Lilly valued at more than US$23bn.

Representing pharmaceutical and biologics companies in connection with numerous federal and state investigations of sales and marketing, pricing, Medicaid rebate, FDCA promotional issues, and cGMP compliance.

Representing provider networks in multiple investigations of their clinical integration and joint negotiations with health plans by federal and/or state antitrust enforcers.

Advising Lilly in its European patent disputes concerning its oncology product, pemetrexed.